ABSTRACT: From a historical perspective, it is difficult to identify a specific date that launched the field of endocrinology. One "biomarker" of the inception of endocrinology traces back to Ernest Henry Starling, who first introduced the word hormone in a talk given in 1905 at the Royal College of Physicians in London (Starling, 1905) . A historical look at the field of endocrine regulation of animal growth since 1905 conveys that countless scientists worldwide worked to advance the scientific evidence base, which led to the commercial development of hormone-based products that enhanced growth and beneficially changed carcass composition of meat animals. This review will discuss some of seminal contributions that include the discovery of hormones (like ST and β-adrenergic agonists) that have been shown to play key roles in regulating growth and nutrient partitioning of livestock, the mechanisms by which these hormones act, and the development of products for application in animal agriculture.
INTRODUCTION
In a short review such as this, not all topics can be discussed. Consequently, I have taken the liberty of focusing on certain topics and referring the interested reader to others. One focal point of this review will be on the GH and ST axis and effects of ST on livestock growth performance (a composite of growth rate, feed efficiency, and carcass composition), including a historical perspective of the initial research that led to the discovery of ST. In addition, an overview of the discovery and application of β-adrenergic agonists in livestock is provided. The scientific advancements made from the late 1970s to the present for ST and β-adrenergic agonists in animal agriculture is a remarkably interesting period. Much was learned about the efficacy and biological mechanisms of ST and β-adrenergic agonists. Moreover, unprecedented discoveries in recombinant DNA technologies permitted large-scale production of recombinant ST. This was a necessary requisite for developing technologies to deliver ST in a manner that was commercially feasible for on-farm application. The latter part of this review will focus on the challenges that lie ahead for the scientific and agribusiness communities, specifically those driven by anti-science and animal activist groups that are intended to hinder the development and application of products of biotechnology for animal agriculture in the future.
HISTORICAL PERSPECTIVES

ST
The early research that is the foundation of our current understanding of ST biology traces back to the pioneering research conducted by Evans and coworkers who first demonstrated the presence of a substance in the anterior pituitary gland that increased the growth rate of rats (Evans and Long, 1922a,b; Evans and Simpson, 1931) . Lee and Schaffer (1934) subsequently established that pair-fed rats injected with an alkaline extract of bovine pituitaries not only gained more BW, but also the composition of the BW gain contained proportionally more muscle and less adipose tissue. Subsequently, research conducted over the following 20 yr led to the discovery that ST was the compound in the alkaline extract that accounted for the growth effects (reviewed in Etherton, 1989) . During this time it became evident that the biological effects of ST extended beyond growth stimulation. It is now well established that ST has a multitude of biological effects that affect a wide array of physiological processes (Table 1) .
It was not until 1951 that Raben and Westermeyer (1951) described a method for the isolation of porcine ST (pST). Because the preparation was quite heterogeneous, a complete chemical characterization was not presented. Subsequently, Papkoff et al. (1962) published a procedure for the preparation of pST from freshly frozen pig pituitary glands and reported that pST had a molecular weight of 41,600 da. With advances in protein chemistry and separation techniques, further improvements in pST purification were achieved (Chen et al., 1970 , Mills et al. (1970 presented the first partial AA sequence data for pST. The complete AA sequence was not established until 1983 when Seeburg et al. (1983) deduced the sequence from a cloned cDNA for pST.
The awareness from the early studies with growing rats that the pituitary gland produced substances that play an important role in the growth process prompted animal scientists to treat pigs with pituitary gland preparations of pST. The early studies (Giles, 1942; Turman and Andrews, 1955; Henricson and Ullberg, 1960) were inconclusive with respect to the effects of these pituitary gland preparations on growth performance of pigs. These negative findings were due to the purity of the ST preparations. In 1972 , Machlin (1972 established that treating pigs with pituitary-derived pST significantly improved BW gain and feed efficiency. At that time, however, there was no obvious cost-effective way to commercialize a pST-based product because of the availability of pig pituitaries and the prohibitive cost of pST purification. Breakthroughs in biotechnology in the early 1980s enabled ST to be produced by recombinant DNA technology.
With the recognition that recombinant pST could be produced, a flurry of studies with pituitary-derived pST were conducted that conclusively demonstrated that treating pigs with exogenous pituitary pST dramatically increased pig growth performance (Chung et al., 1985; Etherton et al., 1986 Etherton et al., , 1987 Campbell et al., 1988) . These studies were quickly followed by the first study to demonstrate efficacy of recombinant pST (Evock et al., 1988) . The magnitude of response in these studies has varied primarily because of differences in experimental design (e.g., initial pig BW, length of study, sex, dose of pST administered, and differences in nutrient content of the diet). One of the interesting physiologi- Modified with permission from Etherton and Bauman, 1998. Growth and development research cal responses observed was that the response to pST increased as pigs gained BW (Evock et al., 1988; Boyd et al., 1991) . King et al. (2000) subsequently demonstrated that efficiency of production was not compromised in heavier pigs (treated from 80 to 120 kg of BW) treated with pST. Collectively, the evidence base has convincingly established that pST increases ADG approximately 10 to 20%, improves feed efficiency 15 to 35%, decreases adipose tissue mass and lipid accretion rates by as much as 50 to 80%, and concurrently increases protein deposition by as much as 50% (reviewed by Etherton and Bauman, 1998) . Much of the scientific literature evaluating the effects of ST administration in livestock and the underlying biological mechanisms has been done with growing pigs. Studies conducted with growing cattle and sheep has shown that administration of exogenous bovine ST (bST) or GHRH has a positive effect on growth performance, but the response in many of these studies is less than observed for pigs (Enright, 1989; Beermann et al., 1990) . The exception to this is that abomasal infusion of casein markedly increases nitrogen retention (Houseknecht et al., 1992) , suggesting that the quantity of AA supplied from microbial and ruminal escape protein in growing cattle limits the nitrogen retention response to bST.
At the time the seminal discoveries were being made in the 1980s/1990s about the effects of recombinant (r) pST and rbST on growth performance of pigs and cattle, there was great anticipation that these products would be approved by the Food and Drug Administration (FDA) for commercial use in the United States. Although rbST was approved by the FDA in 1993 for use in lactating dairy cows (see Etherton and Bauman, 1998) , neither rpST nor rbST were approved for using in growing pigs and cattle in the United States.
β-Adrenergic Agonists
During the boom era of pST research in the 1980s, research also was ongoing evaluating the effects of β-adrenergic agonists (specifically, clenbuterol, cimaterol, and ractopamine) on growth performance and mechanisms of action in meat animals (reviewed in Etherton and Smith, 1991; Mersmann, 1998) for an overview of efficacy and mechanisms of action). The first β-adrenergic agonist studied was clenbuterol, a synthetic analog of epinephrine. Clenbuterol increased dressing percentage, loin-eye area, and overall muscle deposition in wether lambs (Baker et al., 1984; Hamby et al., 1986) and in cattle (Miller et al., 1988; Schiavetta et al., 1990) . Cimaterol, which is structurally similar to clenbuterol, had similar effects in wether lambs (Beermann et al., 1986 (Beermann et al., , 1987 Kim et al., 1987 Kim et al., , 1989 Wang and Beermann, 1988) , intact lambs (Hanrahan et al., 1986) , and steers (Hanrahan et al., 1986) .
Ractopamine, another phenthanolamine possessing β-adrenergic agonist activity, was shown to be an effective agonist for stimulating growth performance in pigs (Anderson et al., 1987; Bergen et al., 1989) and beef cattle Pritchard, 2005; Abney et al., 2007) . Ractopamine has been approved by the FDA for use in growing pigs (Paylean, Elanco Animal Health, Greenfield, IN) and beef cattle (Optaflexx, Elanco Animal Health). More recently, another β-adrenergic agonist, zilpaterol hydrochloride (Intervet Inc., Millsboro, DE), has approved by the FDA for use in feedlot cattle. Studies have shown that zilpaterol hydrochloride fed for 20 to 40 d at the end of the finishing period increases cattle growth performance and muscle deposition (Leheska et al., 2009; Montgomery et al., 2009a,b) .
THREATS TO TECHNOLOGICAL INNOVATION IN ANIMAL AGRICULTURE
The modern era of biotechnology research is a time of remarkable scientific achievements. Nonetheless, some in the public continue a discussion/attack about the need for and safety of biotechnology in the barnyard (see articles posted at http://blogs.das.psu.edu/tetherton/). A recent focal point of these campaigns of misinformation has been the attack on rbST use in the dairy industry, and the deceptive marketing efforts driven by some in the dairy industry to promote sales of rbSTfree milk. Their intent is clear: to differentiate milk and dairy products into 3 niches: 1) conventional, 2) rbSTfree, and 3) organic, and sell the latter 2 products for appreciably more. Moreover, this is being done without paying a fair premium to producers who are forced to abandon use of the rbST. For additional information on this debate, the interested reader is directed to the Terry Etherton Blog on Biotechnology (http://blogs. das.psu.edu/tetherton/) where this topic is discussed in depth.
Before we in the animal agricultural community get carried away anticipating scientific advances in biotechnology over the next 40 yr, there are several key points that must be considered. There is the ever present issue of insufficient funding being available for discovery and applied research in agriculture. Moreover, scientific discoveries that are made require a viable private sector to commercialize new products of biotechnology. This is becoming more challenging. The process of moving a product through the regulatory approval process is becoming more complex, costly, and lengthy. This growing burden makes it challenging for private sector to recover their investment costs from product sales. This is particularly important for agricultural biotechnologies where the margins on products sold are less than biomedical biotechnology products (using comparable scientific methods for production).
A debate that has not taken place to any extent relates to the future of basic science research in animal agriculture. If there is no outlet to commercialize scientific discoveries, then the possibility emerges that federal funding for basic, discovery research could wane; why fund this research if discoveries cannot be commercialized? My encouragement is that we in the animal agricultural community champion the benefits of investing in discovery research that benefits animal agriculture and consumers. At the present time, there are few science activists who effectively represent the best interests of the animal sciences in defending the right to develop and use agricultural biotechnologies in production agriculture.
SUMMARY AND CONCLUSIONS
The history of growth biology research is steeped in many discoveries that have beneficially affected animal agriculture and society. Over the past 100 yr, there has been remarkable scientific progress made by a multitude of scientists worldwide. There is a pressing need over the next 50 yr for animal scientists to make discoveries that lead to new technologies that benefit animal agriculture and society. The scientific and agribusiness communities, however, must become more active and effective advocates in the public discussion about the need for and value of new research funding. This funding will be necessary for the development of new biotechnologies to feed a growing world population and to do so in a way that reduces the environmental footprint of animal agriculture.
